Bank of America backs Pharvaris on breakthrough for rare swelling disease

Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.

Original reporting
Published Oct 26, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bank of America backs Pharvaris on breakthrough for rare swelling disease — source image
Decision brief

The 30-second read

$PHVSBullishHigh
01

Why it matters

The Phase 3 trial data and BofA upgrade provide a clear catalyst that could push the stock higher, especially given the prior price pullback.

02

Market read

First report of pivotal trial data and analyst upgrade creates immediate trading interest in PHVS.

03

What to watch

Potential competition from BioCryst's oral therapy and the need for real‑world adoption data.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Pharvaris (PHVS) is developing oral treatments for hereditary angioedema, a rare disease affecting ~7,500 U.S. patients.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

Bank of America upgraded PHVS to Buy after Phase 3 trial showed 83% attack reduction, keeping a $44 price target.

Expected impact

upward pressure as investors price in the upgrade and strong efficacy data

Evidence & confidence

The upgrade is a fresh catalyst; Phase 3 results are material for a biotech and often trigger price gains.

Market effects

May lift other rare‑disease biotech stocks as investors seek similar pipeline opportunities.

Positive for US biotech sector, modest effect on broader market.

Limited to biotech investors; no broad macro impact.

Counterpoint

If FDA delays or safety concerns emerge, the stock could face sharp downside despite the upgrade.

Key entities

  • Bank of America

    Upgraded PHVS to Buy and maintained a $44 price target.

  • Pharvaris

    Biotech firm reporting Phase 3 trial results for deucrictibant.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.